IPAB sets aside order on anti-viral

Remands the rejected patent for fresh consideration

Image
Gireesh Babu Chennai
Last Updated : Feb 02 2014 | 10:11 PM IST
IPAB sets aside order on anti-viral
"In view of the same we have no hesitation to hold that the impugned order was passed in flagrant violations of principles of natural justice."

"For the foregoing reasons we are constrained to set aside the impugned order and remand the matter to the Assistant

Controller of Patents and Designs in Chennai, for reconsideration of the matter afresh by affording opportunity to all the parties by sending the expert evidences on the Board's examination and furnishing the recommendations of the board to all the parties," said Justice K N Basha.

Also Read


The Assistant Controller of Patents and Designs, Chennai shall reconsider the matter afresh and dispose off the matter within a period of five months from the date of receipt of the order and records from the IPAB bench.

He further added that it is pertinant to note that all the parties in this matter have agreed for hearing the matter from the post-grant stage and the time of disposal of the Special Leave Petiton by the apex court as per order dated March 2, 2009 in SLP Civil Number 3522 of 2009. "Therefore it is made clear that there shall be an order of status quo as on date," he ordered.

The Patent Office has set aside the patent, which was granted to Roche in June 29, 2007, stating that the drug lacked inventive step. The NGOs, however, alleged that the Patent Office did not consider their pre-grant opposition on the patent and later joined the post grant opposition as an arrangement was made in the Supreme Court regarding the opposition.

It may be noted that the IPAB has remanded a dispute of US-based Schering Corporation on a crystalline form of a compound for treatment of heart related disease and a matter  related to patent application of US-based Abraxis BioScience LLC for its anti cancer drug Abraxane in a pre-grant opposition by Hyderabad-based Natco Pharma Ltd, back to the patent office setting aside the earlier order and directing the Assistant Controller to consider the matter afresh.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 02 2014 | 10:10 PM IST

Next Story